Itch relief in patients with psoriasis: effectiveness of calcipotriol plus betamethasone dipropionate foam.
Journal of the European Academy of Dermatology and Venereology : JEADV
BACKGROUND: Itch is common in psoriasis, adversely affecting health-related quality of life (HRQoL) and sleep.
OBJECTIVE: We evaluated the efficacy of topical fixed-dose combination calcipotriol 50 μg/g plus betamethasone dipropionate 0.5 mg/g cutaneous foam (Cal/BD foam) on itch, itch-related sleep loss and HRQoL versus foam vehicle.
METHODS: We pooled data from three Phase II/III trials (NCT01536886/NCT01866163/NCT02132936) of Cal/BD foam versus foam vehicle in adults with mild-severe psoriasis. For itch-related analyses, patients with baseline itch VAS >40 (range 1-100) were analysed. Outcomes included: itch VAS reduction >40, ≥70% improvement in itch (Itch70) or itch-related sleep loss, 75% improvement in modified PASI (excluding head) (mPASI75), and Dermatology Life Quality Index (DLQI) scores 0/1 through 4 weeks.
RESULTS: Of 837 patients, 800 had baseline itch VAS >0 (Cal/BD foam, n=610; foam vehicle, n=190); 484 had baseline itch VAS >40. There was no correlation between itch VAS score and mPASI at baseline (R
CONCLUSION: Compared with foam vehicle, Cal/BD foam offers more rapid and effective itch relief, with associated significant improvements in sleep and DLQI. This article is protected by copyright. All rights reserved.
ePub ahead of print